Tagged with Ipsen

France France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as a benchmark internationally, and which few other countries have proven able to match.   “Back in the mid-2000s, under the…

France Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation. In this conversation, Dominique Bery explains how France is shaping Ipsen’s next phase of growth, from oncology leadership to deeper…

China While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life sciences ecosystem. Eased restrictions on foreign investment have made it even more attractive for international pharma while China’s native innovators…

France At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi, Ipsen, and Pierre Fabre – arguments were made for increasing efficiency in a healthcare system that is “on its last…

China A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive phase III trial results; the strategic partnership between Sino Biological and BioGeometry; CSL’s sale of its China-based plasma collection operations…

China General manager Guillaume Delmotte explores Ipsen’s strategic initiatives in China, highlighting the importance of innovation, addressing healthcare challenges, and fostering a sustainable, people-centric organization. Delmotte emphasizes the rapid pace of change and the vital role of human connections in driving success.   Moving [our China headquarters] to Shanghai allowed Ipsen…

France After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its pipeline. With an FDA green light for its 2017-acquired Onivyde and an expected approval for its Genfit-partnered therapy this year,…

France With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination for international investments, France is looking to boost innovation, attracting the largest number of R&D centres in Europe in 2022,…

France France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has demonstrated its willingness to take steps towards levelling its pricing barometers and in so doing tackle medicine shortages and build…

Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…

Greece Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but ahead of Germany and Italy on trials per capita. However, the pharmaceutical industry does see opportunities for establishing greater trial…

Greece Ipsen’s George Carystinos explains what brought him back to Greece for a first country manager position after a succession of global roles, how the company’s global specialty care transformation is playing out in the Greek market, and why he is optimistic about the impact that Ipsen’s portfolio can have in…